CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

Fei Yi,Tal Cohen,Natalie Zimmerman,Friederike Dündar,Paul Zumbo,Razan Eltilib,Erica J. Brophy,Hannah Arkin,Judith Feucht,Michael V. Gormally,Christopher S. Hackett,Korbinian N. Kropp,Inaki Etxeberria,Smita S. Chandran,Jae H. Park,Katharine C. Hsu,Michel Sadelain,Doron Betel,Christopher A. Klebanoff

DOI: https://doi.org/10.1101/2024.02.26.582108

2024-03-01

Abstract:Chimeric antigen receptor (CAR)-engineered T and NK cells can cause durable remission of B-cell malignancies; however, limited persistence restrains the full potential of these therapies in many patients. The FAS ligand (FAS-L)/FAS pathway governs naturally-occurring lymphocyte homeostasis, yet knowledge of which cells express FAS-L in patients and whether these sources compromise CAR persistence remains incomplete. Here, we constructed a single-cell atlas of diverse cancer types to identify cellular subsets expressing , the gene encoding FAS-L. We discovered that is limited primarily to endogenous T cells, NK cells, and CAR-T cells while tumor and stromal cells express minimal . To establish whether CAR-T/NK cell survival is regulated through FAS-L, we performed competitive fitness assays using lymphocytes modified with or without a FAS dominant negative receptor (ΔFAS). Following adoptive transfer, ΔFAS-expressing CAR-T and CAR-NK cells became enriched across multiple tissues, a phenomenon that mechanistically was reverted through knockout. By contrast, was dispensable for CAR-mediated tumor killing. In multiple models, ΔFAS co-expression by CAR-T and CAR-NK enhanced antitumor efficacy compared with CAR cells alone. Together, these findings reveal that CAR-engineered lymphocyte persistence is governed by a FAS-L/FAS auto-regulatory circuit.

Immunology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the following aspects:

1. **Determine which cell types express FASLG in cancer patients**: The FASLG gene encodes the FAS ligand (FAS - L), and the FAS - L/FAS pathway plays a crucial role in the naturally occurring lymphocyte homeostasis. However, the current understanding of which cells express FASLG in cancer patients and whether these sources will affect the persistence of CAR - T cells is still incomplete.

2. **Explore whether the persistence of CAR - engineered lymphocytes is negatively self - regulated by FASLG**: The researchers hypothesized that activation - dependent FAS - L expression may induce apoptosis through interaction with FAS+CAR - T cells, thereby limiting cell persistence. To test this hypothesis, they conducted competitive fitness experiments using lymphocytes that express or do not express the FAS dominant - negative receptor (ΔFAS).

3. **Determine whether FASLG is necessary for the targeted tumor - killing function of CAR - T and CAR - NK cells**: The researchers hope to clarify whether the FAS - L/FAS pathway affects the anti - tumor effects of CAR - T and CAR - NK cells, especially under different effector - to - target cell ratios (E:T ratio).

Through these studies, the paper aims to reveal that the persistence of CAR - engineered lymphocytes is controlled by a FAS - L/FAS self - regulatory loop and to explore how to enhance the persistence and anti - tumor effects of CAR - T and CAR - NK cells by blocking FAS signals.